These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

434 related items for PubMed ID: 28185212

  • 1. Economic Evaluations of New Oral Anticoagulants for the Prevention of Venous Thromboembolism After Total Hip or Knee Replacement: A Systematic Review.
    Brockbank J, Wolowacz S.
    Pharmacoeconomics; 2017 May; 35(5):517-535. PubMed ID: 28185212
    [Abstract] [Full Text] [Related]

  • 2. Pharmacoeconomic evaluation of dabigatran, rivaroxaban and apixaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement in Spain.
    Gómez-Outes A, Avendaño-Solá C, Terleira-Fernández AI, Vargas-Castrillón E.
    Pharmacoeconomics; 2014 Sep; 32(9):919-36. PubMed ID: 24895235
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The cost-effectiveness of oral direct factor Xa inhibitors compared with low-molecular-weight heparin for the prevention of venous thromboembolism prophylaxis in total hip or knee replacement surgery.
    Mahmoudi M, Sobieraj DM.
    Pharmacotherapy; 2013 Dec; 33(12):1333-40. PubMed ID: 23625693
    [Abstract] [Full Text] [Related]

  • 5. A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the irish healthcare setting.
    McCullagh L, Tilson L, Walsh C, Barry M.
    Pharmacoeconomics; 2009 Dec; 27(10):829-46. PubMed ID: 19803538
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Economic Evaluation of New Oral Anticoagulants in Prevention of Venous Thrombosis Following Joint Replacement Surgery: A Systematic Review.
    Rezapour A, Souresrafil A, Arabloo J.
    Clin Ther; 2021 May; 43(5):e139-e156. PubMed ID: 33875243
    [Abstract] [Full Text] [Related]

  • 8. A Canadian study of the cost-effectiveness of apixaban compared with enoxaparin for post-surgical venous thromboembolism prevention.
    Revankar N, Patterson J, Kadambi A, Raymond V, El-Hadi W.
    Postgrad Med; 2013 Jul; 125(4):141-53. PubMed ID: 23933902
    [Abstract] [Full Text] [Related]

  • 9. [Cost-effectiveness analysis of apixaban compared to dabigatran in the prevention of venous thromboembolism in patients subjected to total knee or hip replacement].
    Gómez-Cerezo JF, Gómez-Arrayás I, Suárez-Fernández C, Betegón-Nicolás L, de Salas-Cansado M, Rubio-Terrés C.
    Rev Esp Cir Ortop Traumatol; 2012 Jul; 56(6):459-70. PubMed ID: 23594943
    [Abstract] [Full Text] [Related]

  • 10. Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a U.S. payer's perspective.
    Duran A, Sengupta N, Diamantopoulos A, Forster F, Kwong L, Lees M.
    Pharmacoeconomics; 2012 Feb 01; 30(2):87-101. PubMed ID: 22187932
    [Abstract] [Full Text] [Related]

  • 11. [Budgetary impact for the National Health System of apixaban prophylaxis of venous thromboembolism in patients undergoing total knee or hip replacement].
    Gómez Arrayas I, Suárez Fernández C, Gómez Cerezo JF, Betegón Nicolás L, de Salas-Cansado M, Rubio-Terrés C.
    Rev Esp Salud Publica; 2012 Dec 01; 86(6):601-12. PubMed ID: 23325135
    [Abstract] [Full Text] [Related]

  • 12. Economic Evaluation of Rivaroxaban Versus Enoxaparin for Prevention of Venous Thromboembolism After Total Knee Replacement and Total Hip Replacement: A Systematic Review.
    Rashki Kemmak A, Abutorabi A, Alipour V.
    Clin Drug Investig; 2020 Aug 01; 40(8):715-725. PubMed ID: 32578155
    [Abstract] [Full Text] [Related]

  • 13. Clinical Effectiveness and Safety of Aspirin for Venous Thromboembolism Prophylaxis After Total Hip and Knee Replacement: A Systematic Review and Meta-analysis of Randomized Clinical Trials.
    Matharu GS, Kunutsor SK, Judge A, Blom AW, Whitehouse MR.
    JAMA Intern Med; 2020 Mar 01; 180(3):376-384. PubMed ID: 32011647
    [Abstract] [Full Text] [Related]

  • 14. Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip or knee surgery: a NICE single technology appraisal.
    Holmes M, Carroll C, Papaioannou D.
    Pharmacoeconomics; 2012 Feb 01; 30(2):137-46. PubMed ID: 22185183
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Cost-effectiveness of rivaroxaban in the prevention of venous thromboembolism: A Canadian analysis using the Ontario Ministry of Health Perspective.
    McDonald H, Diamantopoulos A, Wells P, Lees M, Folkerts K, Forster F, Ananthapavan J.
    J Med Econ; 2012 Feb 01; 15(5):817-28. PubMed ID: 22494267
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.